Enliven Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Enliven Therapeutics (ELVN).

Price Target Range — 10 Quarters

Analyst Consensus — 12 Analysts

12Buy

Consensus RatingBuy# Analysts12Avg. Consensus PT$66Upside to Avg. PT+60.9%

Rating Trend — Last 9 Months

Recent Analyst Actions

Ver todas las valoraciones →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 2, 2026	Morgan Stanley	Sean Laaman	Initiate	Overweight	$70
Oct 1, 2026	JP Morgan	Priyanka Grover	Initiate	Overweight	$75
Aug 18, 2026	William Blair	Andy Hsieh	Initiate	Outperform	—
Aug 18, 2026	Barclays	Etzer Darout	Initiate	Overweight	$78
Aug 18, 2026	Mizuho	Salim Syed	PT Raise	Outperform	$62→$73
Aug 6, 2026	Stifel	Dara Azar	PT Raise	Buy	$80→$82
Aug 6, 2026	Guggenheim	Michael Schmitz	PT Cut	Buy	$80→$78
Aug 6, 2026	Goldman Sachs	Salveen Richter	PT Raise	Buy	$67→$80
Jul 21, 2026	Goldman Sachs	Salveen Richter	PT Raise	Buy	$59→$67
Jul 9, 2026	HC Wainwright & Co.	Robert Burns	PT Raise	Buy	$56→$64
Jul 1, 2026	Stifel	Dara Azar	PT Raise	Buy	$60→$80
Jun 29, 2026	Jones Trading	Boris Peaker	PT Raise	Buy	$45→$70
Jun 9, 2026	Stifel	Dara Azar	Initiate	Buy	$60
Jun 2, 2026	Mizuho	Salim Syed	PT Raise	Outperform	$45→$62
May 8, 2026	Goldman Sachs	Salveen Richter	PT Raise	Buy	$41→$59
Mar 26, 2026	HC Wainwright & Co.	Robert Burns	PT Raise	Buy	$48→$56
Mar 25, 2026	Mizuho	Salim Syed	PT Raise	Outperform	$41→$45
Jul 2, 2025	HC Wainwright & Co.	Robert Burns	PT Raise	Buy	$40→$48
Jun 16, 2025	Goldman Sachs	Salveen Richter	Initiate	Buy	$37
Jun 16, 2025	Baird	Colleen Kusy	PT Raise	Outperform	$40→$52

More with Benzinga EdgeGet Access

Analyst Ratings News

This Enliven Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday

Analysts initiated coverage: VYLR Outperform/$85, LBRX Buy/$68, ELVN Overweight/$70, SAIL Sector Weight, and AVLN Outperform/$60.

Avi Kapoor

PRO
Morgan Stanley Initiates Coverage On Enliven Therapeutics with Overweight Rating, Announces Price Target of $70

Morgan Stanley analyst Sean Laaman initiates coverage on Enliven Therapeutics (NASDAQ:ELVN) with a Overweight rating and announces Price Target of $70.

Benzinga Newsdesk

PRO
JP Morgan Initiates Coverage On Enliven Therapeutics with Overweight Rating, Announces Price Target of $75

JP Morgan analyst Priyanka Grover initiates coverage on Enliven Therapeutics (NASDAQ:ELVN) with a Overweight rating and announces Price Target of $75.

Benzinga Newsdesk

Enliven’s Lead Drug Could Disrupt The Leukemia Treatment Market, Analyst Says

William Blair initiates Enliven Therapeutics (ELVN) with Outperform, highlighting ELVN-001's strong CML trial data & $8.8B market potential.

Vandana Singh

PRO
William Blair Initiates Coverage On Enliven Therapeutics with Outperform Rating

William Blair analyst Andy Hsieh initiates coverage on Enliven Therapeutics (NASDAQ:ELVN) with a Outperform rating.

Benzinga Newsdesk

PRO
Barclays Initiates Coverage On Enliven Therapeutics with Overweight Rating, Announces Price Target of $78

Barclays analyst Etzer Darout initiates coverage on Enliven Therapeutics (NASDAQ:ELVN) with a Overweight rating and announces Price Target of $78.

Benzinga Newsdesk

Enliven Therapeutics Inc

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

Enliven Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

This Enliven Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday

PRO
Morgan Stanley Initiates Coverage On Enliven Therapeutics with Overweight Rating, Announces Price Target of $70

PRO
JP Morgan Initiates Coverage On Enliven Therapeutics with Overweight Rating, Announces Price Target of $75

Enliven’s Lead Drug Could Disrupt The Leukemia Treatment Market, Analyst Says

PRO
William Blair Initiates Coverage On Enliven Therapeutics with Outperform Rating

PRO
Barclays Initiates Coverage On Enliven Therapeutics with Overweight Rating, Announces Price Target of $78

People Also Watch

People Also Watch

Enliven Therapeutics Inc

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

Enliven Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

This Enliven Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday

PROMorgan Stanley Initiates Coverage On Enliven Therapeutics with Overweight Rating, Announces Price Target of $70

PROJP Morgan Initiates Coverage On Enliven Therapeutics with Overweight Rating, Announces Price Target of $75

Enliven’s Lead Drug Could Disrupt The Leukemia Treatment Market, Analyst Says

PROWilliam Blair Initiates Coverage On Enliven Therapeutics with Outperform Rating

PROBarclays Initiates Coverage On Enliven Therapeutics with Overweight Rating, Announces Price Target of $78

People Also Watch

People Also Watch

PRO
Morgan Stanley Initiates Coverage On Enliven Therapeutics with Overweight Rating, Announces Price Target of $70

PRO
JP Morgan Initiates Coverage On Enliven Therapeutics with Overweight Rating, Announces Price Target of $75

PRO
William Blair Initiates Coverage On Enliven Therapeutics with Outperform Rating

PRO
Barclays Initiates Coverage On Enliven Therapeutics with Overweight Rating, Announces Price Target of $78